These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23287696)

  • 1. Subclinical contractility impairment in HIV-infected patients: dependence on the class of antiretroviral drugs.
    Mercuro G; Cadeddu C; Nocco S; Deidda M; Mercuro S; Piano P; Ortu F; Manconi PE
    Int J Cardiol; 2013 Sep; 168(2):1538-9. PubMed ID: 23287696
    [No Abstract]   [Full Text] [Related]  

  • 2. Class of antiretroviral drugs and the risk of myocardial infarction.
    ; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
    N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
    Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
    HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus and atherosclerosis.
    Farrugia PM; Lucariello R; Coppola JT
    Cardiol Rev; 2009; 17(5):211-5. PubMed ID: 19690471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of myocardial infarction in HIV-infected patients receiving HAART: a case report.
    Muise A; Arbess G
    Int J STD AIDS; 2001 Sep; 12(9):612-3. PubMed ID: 11516372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between atazanavir plasma levels and renal function in HIV-positive individuals on antiretroviral therapy with undetectable viral load.
    Luz AJ; Poeta J; Linden R; Antunes MV; Caminha LI; Callegari-Jacques SM; Sprinz E
    Int J Antimicrob Agents; 2013 May; 41(5):497-8. PubMed ID: 23453620
    [No Abstract]   [Full Text] [Related]  

  • 11. [Also consider cardiovascular risk. Every HIV patient "his" HAART].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():58-60. PubMed ID: 19031565
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination antiretroviral therapy and the risk of myocardial infarction.
    Friis-Møller N; Sabin CA; Weber R; d'Arminio Monforte A; El-Sadr WM; Reiss P; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Law MG; Kirk O; Phillips AN; Lundgren JD;
    N Engl J Med; 2003 Nov; 349(21):1993-2003. PubMed ID: 14627784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse interactions with antiretroviral agents: focus on recreational and addiction drugs.
    Vassilev ZP; Marcus SM
    AIDS Read; 2004 Feb; 14(2):96. PubMed ID: 15083804
    [No Abstract]   [Full Text] [Related]  

  • 14. Mortality after myocardial infarction in HIV-infected patients who have initiated HAART.
    Rasmussen LD; Gerstoft J; Kronborg G; Larsen CS; Pedersen G; Obel N
    AIDS; 2007 Apr; 21(7):873-5. PubMed ID: 17415045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiretroviral therapy increases risk of heart attack.
    Gottlieb S
    BMJ; 2003 Nov; 327(7425):1186. PubMed ID: 14630739
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy.
    Alimenti A; Forbes JC; Oberlander TF; Money DM; Grunau RE; Papsdorf MP; Maan E; Cole LJ; Burdge DR
    Pediatrics; 2006 Oct; 118(4):e1139-45. PubMed ID: 16940166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy in HIV.
    Yu A; Berbari E; Temesgen Z
    J Med Liban; 2006; 54(2):74-9. PubMed ID: 17086997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HAART influences the lipids].
    Behrens G
    MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
    [No Abstract]   [Full Text] [Related]  

  • 20. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.
    Kotb R; Vincent I; Dulioust A; Peretti D; Taburet AM; Delfraissy JF; Goujard C
    Eur J Haematol; 2006 Mar; 76(3):269-71. PubMed ID: 16451402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.